Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16  by Sinha, Birandra K. et al.
Volume 221, number 2, 240-244 FEB 05517 January 1988 
Iron-dependent hydroxyl radical formation and DNA damage from 
a novel metabolite of the clinically active antitumor drug VP- 16 
Birandra K. Sinha, Helen M. Eliot and B. Kalayanaraman* 
Clinical Oncology Program, Clinical Pharmacology Branch, NationaI Cancer Institute, National Institutes of Health, 
Bethesda, MD 20892 and *Department of Radiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA 
Received 19 November 1987 
The dihydroxy derivative of VP-16 (DHVP), a novel metabolite of the clinically active antitumor drug VP-16, was cyto- 
toxic to human breast tumor cells. It was found that DHVP chelates iron and catalyzes the formation of hydroxyl radicals 
from hydrogen peroxide and reduced glutathione. Ethanol, polyethylene glycol and f-butanol inhibited the formation 
of DMPO-OH, suggesting that perferryl iron was not involved in OH’ formation. Under conditions which formed hy- 
droxyl radicals, DHVP also induced nicking of SV40 DNA, suggesting that the mechanism of tumor cell killing by DHVP 
may involve iron-dependent free radical formation. 
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1. INTRODUCTION 
VP-16 (fig. 1) is a clinically active antitumor drug 
for the treatment of a number of human 
neoplasms. Studies to elucidate the mechanism of 
action have shown that VP-16 induces DNA 
damage in tumor cells and in isolated nuclei [l-3], 
and topoisomerase II has been identified as the in- 
tracellular enzyme responsible for these DNA 
strand breaks [4]. Since metabolic activation has 
been shown to be important in biological activities 
of a number of antitumor drugs, we have probed 
other biochemical factors responsible for 
VP-16-induced tumor cell killing. Recently, we 
have shown that VP-16 is activated by cytochrome 
P-450 and peroxidases (horseradish and 
prostaglandin synthetase) to reactive intermediates 
which bind irreversibly to cellular macromolecules 
[5-91. We have identified two key metabolites of 
VP-16, o-dihydroxy (DHVP) and o-quinone 
(VP-16-Q) derivatives, as the potentially damaging 
and cytotoxic metabolites (fig. 1). 
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Catechols are known to chelate metal ions, to 
form semiquinone radicals during oxidations, and 
to generate oxygen-dependent toxic free radicals. 
,To identify the possible mechanism of tumor cell 
killing by DHVP and therefore of VP-16, we have 
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Fig.1. Structures of VP-16, and its metabolites DHVP and 
VP-16-Q. 
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examined the iron-dependent hydroxyl radical for- 
mation from this novel metabolite of VP-16, and 
the DNA damage in vitro in the presence of 
DHVP, hydrogen peroxide and reduced 
glutathione (GSH). 
2. MATERIALS AND METHODS 
VP-16 was a gift from Bristol-Myers Co. (Syracuse, NY). The 
o-dihydroxy derivative of VP-16, prepared from VP-16 by ox- 
idative o-demethylation followed by the reduction of the o- 
quinone, was provided by Dr Nemec of Frederick-NC1 
Research Facility, MD. Diethylenetriaminepentaacetic acid 
(DETAPAC), and 5,5-dimethyl-1-pyrroline oxide (DMPO) 
were obtained from Aldrich, WI, DMPO was purified by pass- 
ing over activated charcoal before use. Highly polymerized calf 
thymus DNA (type I), RNA (purified from bakers yeast, type 
XI), and GSH were obtained from Sigma (St. Louis, MO). 
SV40 DNA was obtained from Bethesda Research Laboratories 
(Gaithersburg) and was used without further purification. DNA 
and RNA were freed of metal ions by extensive dialysis against 
0.1% DETAPAC as in [lo]. 
The ESR studies were performed using an IBM-Brucker (ER 
200 D SRC) spectrometer operating at 9.5 GHz and equipped 
with an NMR gaussmeter (ER 035) and a TM cavity. The spin- 
trapping studies were carried out by reacting the pre-formed 
iron-DHVP complexes with 1OOrM Hz02 in 1 ml phosphate- 
buffered saline (pH 7.4) containing 50 mM DMPO and re- 
cording the spectrum. The iron-DHVP complex was prepared 
by reacting 20gM Fe’+ with increasing concentrations of 
DHVP (20-1OOrM) at pH 3.0. When present, DNA or RNA 
(200 pg) was added to the pre-formed complex. 
The antitumor activity of DHVP was determined by colony 
formation assay following a 1 h incubation with human breast 
tumor (MCF-7) cells grown in improved modified essential 
medium containing 5% fetal bovine serum and 50 yg/ml gen- 
tamycin. Briefly, the MCF-7 cells were trypsinized and 500 cells 
were seeded in triplicate in six-well Linbro dishes in 2 ml of the 
medium and allowed to attach for 18 h at 37’C. The medium 
was removed and DHVP dissolved in dimethyl sulfoxide 
(DMSO), diluted with serum-free medium, was added. Follow- 
ing 1 h DHVP exposure, the drug was removed and the cells 
were washed with medium. The cells were then supplemented 
with complete medium and allowed to grow for 12-14 days, 
stained with 0.5% methylene blue in 50% methanol, and the 
colonies were counted. 
The DNA degradation induced by DHVP-iron complexes in 
the presence of either Hz02 or GSH was carried out as de- 
scribed [ll]. Briefly, this consisted of reacting 1OOpM SV40 
DNA (>95% form I) with DHVP (dissolved in polyethylene 
glycol and diluted with 20 mM phosphate buffer, pH 7.4, in a 
final volume of 200~1) in the presence or absence of ferric 
acetohydroxamic acid (1OOrM). In the controls without Fe’+, 
1 mM desferal was added to DNA 5 min before the drug addi- 
tion. The reaction was initiated by adding either Hz02 (100 ,uM) 
or GSH (0.25 mM) and incubation carried out for 2 h at 37°C. 
The reactions were then terminated by adding 1 mM desferal 
followed by two extractions with buffer-saturated phenol. The 
reacted DNA (20 al) was then loaded onto 1% agarose gels and 
a constant current (80 V, 2.5 h) was applied in Tris-acetate buf- 
fer. The gels were stained with ethidium bromide and pictures 
were taken under ultraviolet light. 
3. RESULTS AND DISCUSSION 
The relative cytotoxicity of VP-16 and DHVP is 
shown in fig.2. While VP-16 is fairly active in the 
MCF-7 cell line with an ICSO (concentration re- 
quired to inhibit 50% of colony formation) of 
5 PM, DHVP was less active (25%) with an ICSO of 
20pM under the same conditions. The decreased 
activity of DHVP is probably due to the fact that 
it is more polar than the parent drug. When added 
exogenously to cells under tissue culture condi- 
tions, polar drugs are not taken up, and thus the 
intracellular concentrations are not comparable. 
Since DHVP is a catechol, and the mechanism 
of this antitumor activity of DHVP could involve 
formation of free radicals, we next examined iron- 
dependent OH’ formation using DMPO as a spin- 
trapping agent. Addition of Hz02 to DHVP or 
Fe3+ in the presence of DMPO formed very little 
DMPO-OH spin adduct. However, when Hz02 
was added to a preformed DHVP-Fe3+ complex, a 
large increase in spin adduct formation was 
detected (fig.3), and the maximum DMPO-OH 
was formed at a drug/Fe3+ ratio of 2 (table 1). Ad- 
dition of nucleic acids also stimulated the forma- 
tion of OH’ (table 1). The presence of low-M, 
polyethylene glycol or ethanol inhibited the forma- 
tion of DMPO-OH adducts with concomitant for- 
mation of carbon-centered radical adducts with 
DMPO (fig.3) indicating the formation of free 
OH’. Since perferryl species may be involved in the 
iron-dependent free radical chemistry and have 
been shown to react with most of the quenchers of 
OH’ at an appreciable rate [12], we performed 
spin-trapping experiments in the presence of t- 
butanol. Perferryl species react with t-butanol at a 
much slower rate than the hydroxyl radical. 
t-Butanol inhibited DMPO-OH formation in a 
dose-dependent fashion with the formation of a 
DMPO-carbon-centered radical adduct. These 
observations indicate that the perferryl species is 
not involved in the formation of OH radical from 
DHVP-iron complex and thus appears to be dif- 
ferent from adriamycin, where formation of 
perferryl species has been implicated during the 
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Fig.2. Relative cytotoxicity of VP-16 and DHVP in human 
breast tumor (MCF-7) cell line following 1 h drug treatment in 
colony formation assay. VP-16 (0); DHVP (m). 
reductive activation of the drug in the absence of 
metal ion chelators [ 131. 
Since free radicals have been shown to induce 
DNA damage from anthracycline-iron complexes 
[14,15], we next examined metal-dependent 
destruction of SV40 DNA. In the presence of 
H202, DHVP-Fe 3+ complex was an effective 
catalyst for the nicking of SV40 DNA (fig.4A). 
DHVP or iron alone in the presence of hydrogen 
peroxide was without any effects. VP-16 in the 
presence of Fe3+ caused some (~20%) DNA 
cleavage indicating a slow formation of a reactive 
metabolite, most likely DHVP. Both 1: 1 or 2: 1 
DHVP-Fe3+ complexes were equally effective in 
inducing DNA damage in the viral DNA. GSH was 
also effective when substituted for Hz02 in induc- 
ing this DNA damage (fig.4B) from DHVP-Fe3+ 
complex, however, hydrogen peroxide was a better 
reactant for the DHVP-Fe complex to induce DNA 
nicking. 
Our previous studies have shown that VP-16 
undergoes metabolic activation, catalyzed by 
either cytochrome P-450 or peroxidases, to form 
DHVP and VP-16-Q. We have postulated that 
these bioactivations of VP-16 result in the forma- 
tion of potentially cytotoxic species [5-91. Studies 
reported here show that the dihydroxy derivative 
of VP-16 is cytotoxic to MCF-7 tumor cells 
although it is less active than the parent drug. 
However, the lower antitumor activity of DHVP 
may be due to poor bioavailability to the cells in 
IOG 
Fig.3. ESR spectrum of the DMPO-OH formed in the presence 
of 100 rM HaOr from (A) Fe3+ (20 PM), (B) DHVP (40 FM)- 
Fe3+ (20/M) and (C) identical to (B) except the reaction 
mixture contained 2% polyethylene glycol. ESR settings: field, 
3480 G; modulation frequency, 100 kHz; modulation 
amplitude, 2.0 G; microwave power, 20 G; receiver gain, 5 x 
104. 
tissue culture system as a result of increased polari- 
ty of DHVP. We speculate that the production of 
hydroxyl radical is a mechanism for the antitumor 
effects. We have shown that both peroxide and 
Table 1 
Hydroxyl radical formation from DHVP-Fe’+ as a function of 
drug/iron ratio and effects of nucleic acids 
Reactant Relative DMPO-OH 
Iron, alone 1 
DHVP-Fe (1: 1) 16 
DHVP-Fe (2 : 1) 32.5 
DHVP-Fe (3 : 1) 30 
DHVP-Fe (5 : 1) 32.5 
DHVP-Fe (2 : 1) + DNA (200 pg) 45 
DHVP-Fe (2: 1) + RNA (200/g) 52 
The reaction mixtures contained in 1 ml: 20pM Fe’+, DHVP, 
and DMPO with or without nucleic acids. The reaction was 
initiated by adding 1OOpM Hz02. The relative OH formation 
was obtained by monitoring the peak heights of the DMPO-OH 
signal and is given in arbitrary units 
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Fig.4. Hydrogen peroxide (A, 1OOpM) and GSH (B, 250/M) dependent DNA cleavage of SV40 by DHVP-Fe3+. (A) (1) DHVP 
(200 PM)-Fe (100 ,uM); (2) DHVP (100 PM)-Fe’+ (100 PM); (3) Fe3+; (4) DHVP (100 PM) desferal was added to DNA before DHVP 
addition; (5) VP-16 (lOOpM)-Fe’+ (1OOrM); (6) VP-16 (100/M); (7) HzOZ, and (8) control DNA. (B) (1) DHVP (2OOcM)-Fe’+ 
(100 pM); (2) DHVP (100 PM)-Fe’+ (100 PM); (3) Fe’+ (100 ,uM); (4) DHVP (100 ,uM), desferal was added before DHVP addition; 
(5) VP-16 (lOOpM)-Fe3+ (1OOpM); (6) VP-16 (lOOcM), and (7) control DNA. See section 2 for details. 
GSH act as the reductants of oxygen to OH’ with 
the drug-iron complex. Since neither DHVP nor 
Fe3+ alone produced any significant amounts of 
OH’, it appears that DHVP chelation or binding to 
Fe3+ results in the reduction of Fe3+ to Fe2+ since 
peroxide-dependent OH’ formation requires Fe’+ 
in the Fenton system. A significant stimulation of 
OH’ formation in the presence of DNA or RNA 
would suggest that Fe2+ formed is stabilized from 
polymerization, and that this stabilized form is 
redox active as previously observed by Floyd and 
Lewis [ 161. In the present study, we have identified 
DNA as one of the targets for the DHVP- 
dependent iron-mediated damage for the cytotox- 
icity of DHVP. The damage is catalyzed by the 
formation of hydroxyl radicals. It is of interest to 
note that in this mechanism of antitumor activity 
of DHVP and possibly VP-16, there is a direct 
radical-dependent DNA damage which does not 
require participation of topoisomerase II for its ac- 
tivity. It is interesting to speculate, however, that 
OH’ formed from DHVP-iron complex may ox- 
idize SH groups of topoisomerase II causing its in- 
activation. It is not known at this time how iron 
would become available for this free radical- 
dependent DNA damage to occur in vivo. 
However, it must be pointed out that the forma- 
tion of DHVP-iron-dependent free radical would 
be important in certain proliferating tumor cells 
which contain large iron pools [ 17,181. Alter- 
natively, iron may be mobilized from ferritin in 
reactions involving radicals [19,20]. 
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